XFOR, US98420X2027

X4 Pharmaceuticals stock: Wells Fargo keeps Buy rating for X4 Pharmaceuticals stock at USD 11.00

Published on 10/28/2026 at 06:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

X4 will review its Phase 3 trial on October 29, 2026. X4 Pharmaceuticals stock has a USD 322.2 million market value.

Funding and trial calendar

Wells Fargo maintained a Buy rating and set a USD 11.00 target on October 23, 2026.
X4 secured access to USD 150 million in debt financing on October 8, 2026.
The virtual Investor Day is scheduled for October 29, 2026.

XFOR, US98420X2027, Illustration mit AI erstellt.

X4 Pharmaceuticals (ISIN US98420X2027) retained a Buy rating with a USD 11.00 price target in a Wells Fargo analyst note dated October 23, 2026, as reported by Markets Insider. The next company event is a virtual Investor Day scheduled for October 29, 2026, with management set to discuss the Phase 3 4WARD trial and a planned Phase 2 study.

Analyst target meets trial calendar

The USD 11.00 target stands against a recent US market quote of USD 3.25 on October 27, 2026, while the company had a market capitalization of USD 322.2 million as of October 28, 2026. The analyst target therefore places emphasis on clinical execution rather than current commercial scale.

What does the financing change?

X4 announced on October 8, 2026, that it had secured a senior secured term loan facility of up to USD 150 million with K2 HealthVentures, according to the X4 Pharmaceuticals release. The first tranche was USD 80 million and repaid USD 75 million of principal and related fees under the previous facility. The new loan has a 48-month maturity, while a further USD 70 million remains subject to approval and other conditions.

Three milestones since October

On October 1, 2026, X4 granted options for 80,000 common shares at an exercise price of USD 2.90, according to X4 Pharmaceuticals. On October 8, the company announced the USD 150 million facility. On October 9, it announced the October 29 Investor Day, where management will address the 4WARD trial and a proposed combination study involving mavorixafor and granulocyte colony-stimulating factor, as reported by GlobeNewswire.

Dates for the next readout

The October 29, 2026, Investor Day is the next scheduled company event. X4 also expects to complete enrollment in the Phase 3 4WARD trial by the end of 2026 and report topline data in the first half of 2028, according to its October 8 release.

Market value and development risk

X4's market capitalization was USD 322.2 million as of October 28, 2026, and its 52-week range was USD 2.43 to USD 4.83 as of October 27, 2026. The financing extends liquidity options, but access to the remaining USD 70 million depends on lender approval and specified conditions.